Form 4: Cadrenal CEO Pham Executes Planned Stock Sale

Cadrenal Therapeutics CEO Quang Pham sold a total of 652 shares of common stock under a pre-established Rule 10b5-1 trading plan.

Summary

• CEO and Chairman Quang Pham sold 303 shares on May 29, 2026, at a weighted average price of $5.01.
• CEO and Chairman Quang Pham sold 349 shares on June 2, 2026, at a weighted average price of $4.46.
• The sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2025.
• Following these transactions, the reporting person directly owns 181,509 shares and maintains indirect ownership of 200,000 shares via The PVBQ Living Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sales were executed under a pre-existing, automated trading plan and represent a relatively small portion of the executive's total holdings.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 plan, which is a standard mechanism for insiders to sell stock without triggering concerns regarding non-public information.

Negatives

• The sale of shares by the CEO and Chairman may be perceived by some investors as a lack of long-term confidence, despite the pre-planned nature of the transaction.

Risks

• The company is subject to the inherent risks of the pharmaceutical development industry, including clinical trial outcomes and regulatory approval processes.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing, as it is a standard disclosure of insider equity transactions.

Industry Context

StockSavvy.ai notes that insider selling via Rule 10b5-1 plans is a common practice in the biotech sector, allowing executives to diversify holdings while maintaining compliance with SEC regulations.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to manage equity holdings to avoid allegations of insider trading.

Related Party Transactions

• The PVBQ Living Trust, of which Mr. Pham is the Trustee and his child is the beneficiary, holds 200,000 shares.

Stakeholder Impact

• Minimal impact expected as the sales were pre-planned and represent a small fraction of the total outstanding shares.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Cadrenal Therapeutics, CVKD, Insider Trading, Form 4, Quang Pham, Biotech